Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2020-05-07 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general report for foreign private issuers often filed with the SEC, but here it is being filed with the Israel Securities Authority/Tel Aviv Stock Exchange). According to Rule 2, when a document is short and announces the attachment or publication of a primary report, it should be classified as a Report Publication Announcement (RPA). Since RPA is a defined category, it takes precedence over the general fallback (RNS).
2020-05-07 English
20-F for 2019
Annual Report Classification · 1% confidence The document is explicitly titled 'FORM 20-F' and 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934'. It covers the fiscal year ended December 31, 2019, for Enlivex Therapeutics Ltd. Form 20-F is the standard annual report filing for foreign private issuers in the United States, which corresponds to the '10-K' category in the provided schema. FY 2019
2020-05-01 English
20-F for 2019
Report Publication Announcement Classification · 1% confidence The document is a short notification (1930 characters) from Enlivex Therapeutics Ltd to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 20-F' and provides a filename '20FEnlivex_isa.pdf'. According to the 'Menu vs Meal' rule, since this is a short announcement stating that a report is attached rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2019
2020-05-01 English
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for a 'Report of Foreign Private Issuer' under the Securities Exchange Act of 1934. The content is a press release announcing a grant award from the Israel Innovation Authority, which is being furnished as an exhibit to the Form 6-K. Since Form 6-K is a general reporting requirement for foreign private issuers, and it does not map directly to the specific US GAAP/Regulation S-K reports like 10-K or DEF 14A, it falls best under the 'Regulatory Filings' category (RNS) as a general regulatory submission that doesn't fit the other specific definitions (like ER, IR, or CT). Although it contains an earnings-like announcement (grant), the primary structure is the SEC Form 6-K filing itself.
2020-04-13 English
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
Report Publication Announcement Classification · 1% confidence The document is very short (1775 characters) and explicitly states, "Attached hereto is a report on *6-k* *6K_13042020_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general report for foreign private issuers often filed with the SEC, but here it is being reported to the ISA/TASE). According to Rule 2, when a document is short and announces the attachment or publication of a report, it should be classified as a Report Publication Announcement (RPA). Since this is a regulatory filing announcement, RPA is the most appropriate specific code, rather than the general fallback RNS.
2020-04-13 English
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934" and is filed on "Form 6-K" for the month of "March 2020". Form 6-K filings are typically used by foreign private issuers to report material information to the SEC, often mirroring press releases or other material events. The content is a press release announcing positive final safety and efficacy data from a Phase Ib clinical trial for AllocetraTM in severe sepsis patients. This type of announcement, which details periodic financial/operational results (even if clinical trial focused) and is filed on a standard SEC form (6-K), is best classified as an Earnings Release (ER) if it were quarterly results, or more generally, a report of material information. Since the document is a full press release detailing results, it functions as an initial announcement of performance/results, fitting the description of an Earnings Release (ER) better than the general Regulatory Filings (RNS), although 6-K is a regulatory filing. However, given the specific definitions, ER covers initial announcements of periodical financial results (clinical trial results often substitute for financial results in biotech). Since the document is a full press release detailing results, and not just an announcement *about* a report (RPA), ER is the most appropriate fit among the specific options for reporting results.
2020-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.